Open AccessA study of orbital mucormycosis cases at a tertiary hospital
Author(s) -
Snehal Phalke,
Arundhati Pande
Publication year - 2022
Publication title -
indian journal of clinical and experimental opthalmology
Language(s) - English
Resource type - Journals
eISSN - 2395-1451
pISSN - 2395-1443
DOI - 10.18231/j.ijceo.2022.026
Subject(s) - medicine , mucormycosis , medical microbiology , surgery , incidence (geometry) , paranasal sinuses , amphotericin b , prospective cohort study , pediatrics , dermatology , antifungal , physics , virology , optics
The aims of this study was to identify demographic data risk factors for the disease, clinical presentation and treatment outcome of patients having COVID-19 related mucormycosis.This was a prospective, interventional study done in a tertiary hospital carried out from May 2021 to July 2021. With 40 patients under study, the mean age of patients was 52.4 years. The incidence was more in males (80%) than in females. 95% patient had history of COVID-19. In these patient, the treatment of COVID-19 received were either Steroids (92%), O2 therapy (57.5%) or had an ICU stay (37.5%). T2DM was present in 62.5% while T1DM in 2.5%. These patients mainly received intravenous amphotericin-b (92.5%) along with syrup posaconazole as medical management. functional endoscopic sinus surgery (FESS) was done in all the patients while maxillary debridement or maxillectomy was done in 42.5% patients. In ophthalmic conservative line of management 37.5% received transcutaneous retrobulbar amphotericin B (TRAMB). 10% patients underwent exenteration who presented in later stages of the disease. Inspite of all the interventions, 22.5% succumbed due to low health conditions. Corticosteroids followed by DM were the commonest pre-disposing factor for COVID-19 related mucormycosis. Early FESS and timely TRAMB reduced the spread of the disease and conserved vision respectively.